+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sjogren's Syndrome (SS) - Opportunity Analysis and Forecasts to 2029

  • ID: 5304799
  • Report
  • February 2021
  • Region: Global
  • 118 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • BMS
  • Galapagos
  • Gilead
  • GSK
  • Kronos Bio
  • Novartis
  • MORE
Sjogren's Syndrome (SS) - Opportunity Analysis and Forecasts to 2029

Summary

Sjögren’s syndrome (SS) is a chronic and systemic autoimmune inflammatory disorder in which an initial immunological attack that primarily targets the lacrimal and salivary glands. Although most characteristically clinical features are ocular and oral dryness due to reduced secretory functions, systemic features including cutaneous, respiratory, renal, hepatic, neurological, and vascular involvement often occur. In addition, there is a higher incidence of lymphoma associated with SS patients.

The SS market is expected to undergo significant change and moderate growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. In this report, the publisher analyses the current symptomatic SS treatment landscape and provides detailed insights into the market dynamics of this systemic autoimmune disease. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for SS, and their sales projections within SS over the 2019-2029 forecast period.

The SS market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. In this report, the publisher analyzes the current SS symptomatic and systemic treatment landscape and provides detailed insights into the market dynamics of this autoimmune disease. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for SS, and their sales projections within SS over the 2019-2029 forecast period.

With no currently approved systemic treatments, the SS treatment algorithm varies among physicians and institutions, but is largely consists of off-label therapies, immunosuppressants, and corticosteroids. Over the forecast period the publisher expects that treatment options for SS patients will significantly expand as pipeline products are approved and launched for the systemic treatment of SS. The launches of products with demonstrated efficacy will be a major driver of growth over the next 10 years.

Key Questions Answered
  • How will the symptomatic and systemic SS treatment landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2019-2029?
  • What SS treatments are in clinical development?
  • How do the clinical and commercial attributes of SS treatment candidates in development compare with one another, and against conventional treatment options?
  • What are the remaining unmet needs in SS diagnosis and treatment?
  • What drivers and barriers will affect SS sales in the 7MM over the forecast period?
Scope
  • Overview of therapies used in symptomatic, conventional and off-label systemic treatments in SS.
  • Top-line SS treatment market revenue from 2019-2029. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include currently available treatments and off-label products, unmet needs and opportunities, and the drivers and barriers affecting SS sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.
  • Analysis of the current and future market competition in the global SS market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global SS treatment market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • BMS
  • Galapagos
  • Gilead
  • GSK
  • Kronos Bio
  • Novartis
  • MORE
1. Table of Contents

2 Sjögren’s Syndrome: Executive Summary
2.1 Growth in the Sjögren’s Syndrome Market Is Expected from 2019 to 2029
2.2 R&D Strategies for the Sjögren’s Syndrome Market
2.3 High Level of Unmet Need Persists in the Sjögren’s Syndrome Marketplace
2.4 The Arrival of Novel Biologics Will Transform the Sjögren’s Syndrome Treatment Paradigm
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Symptoms
4.1.4 Prognosis
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 Diagnosed Prevalence of SS (%)
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Sources Not Used
5.4.3 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for SS (2019-2029)
5.5.1 Diagnosed Prevalent Cases of pSS
5.5.2 Diagnosed Prevalent Cases of sSS
5.5.3 Age-Specific Diagnosed Prevalent Cases of pSS
5.5.4 Sex-Specific Diagnosed Prevalent Cases of pSS
5.5.5 Diagnosed Prevalent Cases of pSS by ESSDAI
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Current Treatment Options
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Approval of Treatments for Glandular and Extraglandular Manifestations
7.3 Earlier Sjögren’s Syndrome Diagnosis
7.4 Improved Public and Patient Awareness of Sjögren’s Syndrome
7.5 Better Clinical Trial Endpoints

8 R&D Strategies
8.1 Overview
8.1.1 Evaluation of Biologic Therapies Marketed for Other Autoimmune Diseases
8.1.2 Increasing Efficiency of Clinical Trials
8.2 Clinical Trials Design
8.2.1 Endpoint Selection
8.2.2 Inclusion Criteria
8.2.3 Patient Recruitment

9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development

10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan

11 Appendix

List of Tables
Table 1: Sjögren’s Syndrome: Key Metrics in the 7MM
Table 2: Classification Criteria for Sjögren’s Syndrome
Table 3: The EULAR Sjögren's syndrome disease activity index (ESSDAI)
Table 4: Risk Factors and Comorbidities for SS
Table 5: Key Marketed and Off-Label Products for Sjögren’s Syndrome, 7MM
Table 6: Innovative Early-Stage Approaches for Sjögren’s Syndrome, 2021
Table 7: Drugs in Development for Sjögren’s Syndrome, 2021
Table 8: Clinical Benchmark of Key Pipeline Drugs - SS
Table 9: Commercial Benchmark of Key Pipeline Drugs - SS
Table 10: Key Events Impacting Sales for Primary Sjögren’s Syndrome, 2019-2029
Table 11: Primary Sjögren’s Syndrome Market - Global Drivers and Barriers, 2019-2029
Table 12: Key Historical and Projected Launch Dates for Sjögren’s Syndrome
Table 13: Key Historical and Projected Patent Expiry Dates for Sjögren’s Syndrome
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for Sjögren’s Syndrome in 2019 and 2029
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs for Sjögren’s Syndrome Benchmarked Against Off-Label Orencia
Figure 3: Pathophysiology of Sjögren’s Syndrome
Figure 4: 7MM, Diagnosed Prevalence of SS (%), Men and Women, ≥18 Years, 2019
Figure 5: 7MM, Sources Used and Not Used for the Diagnosed Prevalence of pSS
Figure 6: 7MM, Sources Used for the Diagnosed Prevalence of sSS
Figure 7: 7MM, Sources Used for the Diagnosed Prevalence of pSS by ESSDAI
Figure 8: 7MM, Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
Figure 9: 7MM, Diagnosed Prevalent Cases of sSS, Men and Women, Ages ≥18 Years, 2019
Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
Figure 12: 7MM, Diagnosed Prevalent Cases of pSS by ESSDAI, Men and Women, Ages ≥18 Years, 2019
Figure 13: Unmet Needs and Opportunities in Sjögren’s Syndrome
Figure 14: Overview of the Development Pipeline in Sjögren’s Syndrome
Figure 15: Key Phase II/III Trials for the Promising Pipeline Agents that the Publisher Expects to Be Licensed for Sjögren’s Syndrome in the 7MM During the Forecast Period
Figure 16: Competitive Assessment of Pipeline Drugs Benchmarked Against Off-Label Therapy, Orencia
Figure 17: Global (7MM) Sales Forecast by Country for Primary Sjögren’s Syndrome in 2019 and 2029
Figure 18: Global Sales Forecast by Class for Primary Sjögren’s Syndrome in 2019 and 2029
Figure 19: Sales Forecast by Class for Primary Sjögren’s Syndrome in the US in 2019 and 2029
Figure 20: Sales Forecast by Class for Primary Sjögren’s Syndrome in the 5EU in 2019 and 2029
Figure 21: Sales Forecast by Class for Primary Sjögren’s Syndrome in Japan in 2019 and 2029
Note: Product cover images may vary from those shown
3 of 3
  • Viela Bio
  • Gilead
  • Galapagos
  • Novartis
  • Kronos Bio
  • BMS
  • GSK
  • TearSolutions
Note: Product cover images may vary from those shown
Adroll
adroll